

SALIX PHARMACEUTICALS LTD

Form 8-K

January 09, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 8, 2015

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

000-23265
(Commission

File Number)

94-3267443
(I.R.S. Employer
Identification No.)

8510 Colonnade Center Drive

Raleigh, North Carolina
(Address of principal executive offices)

27615
(Zip Code)

Registrant's telephone number, including area code: (919) 862-1000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On January 8, 2015, Salix Pharmaceuticals, Ltd. and Pharming Group NV announced that the first patient was treated in their Phase 2 clinical study of Ruconest® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for prophylaxis in patients with hereditary angioedema. A copy of the joint press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
99.1	Joint press release, dated January 8, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 9, 2015

SALIX PHARMACEUTICALS, LTD.

By: /s/ Timothy J. Creech
Timothy J. Creech
Senior Vice President, Finance and Administrative Services, and
Acting Chief Financial Officer

EXHIBIT INDEX

Exhibit

No.	Description
99.1	Joint press release, dated January 8, 2015.